EMA Aims To Carry On With EU GMP Annex 1 Revision Despite Brexit-Related Staff Departures

The European Medicines Agency is continuing to work on revising Annex 1 of the EU GMP guideline even as the agency focuses more on core tasks like responding to urgent public health threats amid greater-than-expected staff departures in advance of its Brexit-driven move from London to Amsterdam.

bended scientist works with manufacture machine

Despite staff reductions related to the European Medicines Agency’s move from London to Amsterdam, there appears to be a consensus within the agency to continue revising the EU GMP guideline’s Annex 1 on the manufacture of sterile medicinal products, UK Medicines and Healthcare products Regulatory Agency inspector Andrew Hopkins said Oct. 15.

Hopkins, who serves as rapporteur for the guideline’s revision, indicated the revision will take a lot of work. The Annex...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography